OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Crizotinib"

In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene ( ALK ) have been associated with marked clinical responses to Crizotinib ( Xalkori ), an oral tyrosine kinas ...


Non–small-cell lung cancer ( NSCLC ) harboring the anaplastic lymphoma kinase gene ( ALK ) rearrangement is sensitive to the ALK inhibitor Crizotinib ( Xalkori ), but resistance invariably develops. ...


The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer ( NSCLC ) is unknown. A ...


Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor ( ALKi ), shrank tumours ( overall response rate; ORR: 50% ...


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...


A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing cells with increased MET gene copy ...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...


Final, mature progression-free survival ( PFS ) from the global phase III ALEX study of Alectinib ( Alecensa ) vs Crizotinib ( Xalkori ) in untreated, advanced / metastatic anaplastic lymphoma kinase- ...


Ensartinib is a novel second-generation ALK tyrosine kinase inhibitor ( TKI ). In phase 1/2 studies, Ensartinib showed promising activity in patients with ALK+ non-small cell lung cancer ( NSCLC ) who ...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib ( Xalkori ) in treatment-naive ALK-positive non-small-cell lung c ...


Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status in patients with advanced ALK immunohistochemistry ( ...